[1] Søreide K. Epidemiology of major trauma[J]. Br J Surg, 2009 Jul,96(7):697-698. [2] Manson J, Thiemermann C, Brohi K.Trauma alarmins as activators of damage-induced inflammation[J]. Br J Surg,2012,99(Suppl 1):12-20. [3] Keel M, Trentz O.Pathophysiology of polytrauma[J]. Injury,2005,36(6):691-709. [4] Cayrol C, Girard JP.IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy[J]. Curr Opin Immunol,2014,31:31-37. [5] Gadani SP, Walsh JT, Smirnov I, et al.The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury[J]. Neuron,2015,85(4):703-709. [6] 冯刚, 陈庆, 郭恩伟, 等. 创伤患者血清IL-33和sST2的变化及意义[J]. 中国急救医学,2016,36(10):904-907. [7] Mildner M, Storka A, Lichtenauer M, et al.Primary sources and immunological prerequisites for sST2 secretion in humans[J]. Cardiovasc Res,2010,87(4):769-777. [8] Weinberg EO, Shimpo M, De Keulenaer GW, et al.Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction[J]. Circulation,2002,106(23):2961-2966. [9] Nagata A, Takezako N, Tamemoto H, et al.Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells[J]. Cell Mol Immunol,2012,9(5):399-409. [10] Takezako N, Hayakawa M, Hayakawa H, et al.ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells[J]. Biochem Biophys Res Commun,2006,341(2):425-432. [11] Gao S, Huan SL, Han LY, et al.Overexpression of serum sST2 is associated with poor prognosis in acute-on-chronic hepatitis B liver failure[J]. Clin Res Hepatol Gastroenterol,2015,39(3):315-323. [12] Bao YS, Na SP, Zhang P, et al.Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease[J]. J Clin Immunol,2012,32(3):587-594. [13] Coglianese EE, Larson MG, Vasan RS, et al.Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study[J]. Clin Chem,2012,58(12):1673-1681. [14] Miller AM, Purves D, McConnachie A, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?[J]. PLoS One,2012,7(10):e47830. [15] Caporali A, Meloni M, Miller AM, et al.Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia[J]. Arterioscler Thromb Vasc Biol,2012,32(12):e149-e160. [16] Zhang K, Zhang XC, Mi YH, et al.Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction[J]. Chin Med J (Engl),2013,126(19):3628-3631. [17] Bergis D, Kassis V, Ranglack A, et al.High Serum Leve-ls of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma[J]. Transl Oncol,2013,6(3):311-318. [18] Dieplinger B, Mueller T.Soluble ST2 in heart failure[J]. Clin Chim Acta,2015,443:57-70. [19] Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study[J]. Clin Chem,2013,59(3):536-546. [20] Xu J, Guardado J, Hoffman R, et al.IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model[J]. PLoS Med,2017,14(7):e1002365. |